Advertisement

Topics

Novartis Survey Reveals Burden of Myeloproliferative Neoplasms (Rare Blood Cancers) on Patients' Daily Activity and Ability to Work, Calling for More Proactive Symptom Assessment

03:41 EDT 23 Jun 2017 | FinanzNachrichten

CAMBERLEY, England, June 23, 2017 /PRNewswire/ -- Findings showmore than aquarter of myeloproliferative neoplasm (MPN) patients are managed with watchful waiting at diagnosis, despite one in five ...

Original Article: Novartis Survey Reveals Burden of Myeloproliferative Neoplasms (Rare Blood Cancers) on Patients' Daily Activity and Ability to Work, Calling for More Proactive Symptom Assessment

NEXT ARTICLE

More From BioPortfolio on "Novartis Survey Reveals Burden of Myeloproliferative Neoplasms (Rare Blood Cancers) on Patients' Daily Activity and Ability to Work, Calling for More Proactive Symptom Assessment"

Advertisement
Quick Search
Advertisement
Advertisement